Effective and safe treatment of fibrosis, the hallmark of virtually all end stage organ diseases, is one of the biggest clinical challenges for the next decade. By then, liver fibrosis following NASH and kidney fibrosis following diabetic nephropathy, will rank the top 3 clinical indications with high (unmet) medical need.
Read More ...
BOT501 and BOT191
are BiOrion’s two development candidates for, respectively, non-invasive imaging and targeted treatment, of liver and renal fibrosis. BOT191 is a novel engineered interferon peptide conjugate, combining a targeted antifbrotic effect without unwanted interferon side effects.
It is our mission to confirm the excellent efficacy / safety profile of our development candidates in clinical studies in patients suffering from fibrosis.
BiOrion is currently focusing on 2 drug development programs which are aimed at targeted therapies and diagnostics for liver fibrosis following NASH and renal fibrosis following Diabetic Nephropathy, suited to cause break-through innovation.
BiOrion’s additional development program represents myofibroblasts-targeted liposomes allowing selective delivery of antifibrotic or cytotoxic drugs for which a targeted formulation is demanded.
Fibrosis is dysregulated wound healing. It is the consequence of chronic tissue injury and inflammation, resulting in repetitive formation of extracellular matrix such as collagen, that in turn leads to architectural disruption and organ failure and ultimately to death. The primary cells responsible for fibrosis are myofibroblasts ....
PDGF is one of many growth factors that regulate cell growth and division. It is also a prominent stimulator of fibroblast proliferation during fibrosis. In liver fibrosis, PDGF is the most important mediator involved in the proliferation and activation of hepatic stellate cells, which transform subsequently into myofibroblasts....
BiOrion's core technology is based on proprietary PDGF-ß-receptor binding bicyclic octa-peptides, derived from the amino acid binding sequence of its natural ligand PDGF-BB. This bicyclic peptide can be conjugated to (antifibrotic) drugs (e.g. BOT191) or they can be incorporated onto liposomes containing....